Observational studyAesthetic plastic surgery2026
Preoperative GLP-1 Receptor Agonists and Thromboinflammatory Markers in Patients Undergoing Abdominoplasty: A Prospective Monocentric Study.
Observational study in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbdominoplasty in patients with obesity carries a heightened risk of venous thromboembolism (VTE) due to a proinflammatory and hypercoagulable baseline. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight loss and have demonstrated anti-inflammatory and antithrombotic properties, but their role in aesthetic surgery remains unexplored.
methodsWe conducted a prospective, monocentric, observational study of 60 female patients (BMI ≥ 30 kg/m
resultsWeight loss and preoperative metabolic profiles were comparable between groups. Postoperatively, biomarker increases were significantly attenuated in the GLP-1 RA group: CRP (+ 18 vs. + 28 mg/L, p < 0.01), IL-6 (+ 12 vs. + 20 pg/mL, p < 0.01), fibrinogen (+ 40 vs. + 65 mg/dL, p = 0.02), D-dimer (+ 0.8 vs. + 1.3 µg/mL, p < 0.01), and PAI-1 (+ 5 vs. + 9 ng/mL, p < 0.05). No symptomatic VTE occurred in the GLP-1 group versus two cases (6.7%) in controls; subclinical DVT occurred in 1 (3.3%) versus 3 (10%), respectively. Hospital stay was shorter with GLP-1 therapy (1.8 vs. 2.2 days, p = 0.04).
conclusionsPreoperative GLP-1 RA therapy was associated with reduced perioperative thromboinflammatory response and a favorable trend toward fewer VTE events and complications, despite equivalent weight loss. GLP-1 RAs may provide dual benefits-metabolic optimization and risk modulation-in high-BMI abdominoplasty candidates. Larger randomized trials are warranted. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41944875What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.